Angiotensin receptor blockers (ARBs), also known as sartans, block the activation of angiotensin type 1 receptors and have a recognised role in the treatment of heart failure and nephropathy. Since 2002, there have been three major outcome trials of ARBs in hypertension. We performed a meta-analysis to evaluate the impact of ARB on major outcomes. Randomised controlled trials of ARBs in hypertensive subjects with an average follow-up of at least 2 years and at least 100 major cardiovascular events were included. For each trial, the ARB used, number and characteristics of subjects, baseline and change in blood pressure, cardiovascular and noncardiovascular outcomes were recorded. Three trials involving 29 375 subjects were included in the meta-analysis. In Losartan Intervention For Endpoint (LIFE) and Study on Cognition and Prognosis in the Elderly (SCOPE) but not in Valsartan Antihypertensive Long-term Use Evaluation trial (VA-LUE), an ARB reduced the occurrence of the primary end point and stroke compared to control. Compared to other antihypertensive drugs, ARB treatment was associated with no significant change in all-cause mortality (relative risk ratio (RRR) 0.96, 95% CI: 0.88-1.06, P ¼ 0.45). There was an increase in myocardial infarction (RRR, 1.12, 95% CI: 1.01-1.26, P ¼ 0.041), but a decrease in new-onset diabetes mellitus (RRR, 0.80, 95% CI: 0.74-0.86, Po0.0000001). In conclusion, the reduction in newonset diabetes partly offsets any increase in the risk of myocardial infarction. Most hypertensive patients require more than one class of drugs. Small differences in treatment outcome should not over-ride the importance of good blood pressure control.
Introduction
Angiotensin receptor blockers (ARBs), also known as sartans, block the activation of angiotensin type 1 receptors and have a recognised role in the treatment of heart failure [1] [2] [3] [4] and nephropathy. [5] [6] [7] Nevertheless, the drug class that is best for one indication might not automatically be the first choice for another indication such as essential hypertension. Angiotensin-converting enzyme inhibitors (ACEIs) have a key role in the treatment of heart failure and nephropathy, but are equivalent to other antihypertensive classes in randomised trials. [8] [9] [10] Therefore, clinical trials of ARBs in hypertensive patients are necessary to establish their effectiveness in preventing adverse cardiovascular outcomes.
The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) showed that a losartanbased regimen was superior to an atenolol-based regimen in preventing cardiovascular events (mainly strokes) in hypertensive patients with electrographic left ventricular hypertrophy. 11 The favourable results in LIFE have led to claims that ARBs are of special value to patients with left ventricular hypertrophy and in preventing strokes. However, the better outcome in the losartan group might have been due to atenolol being a poor antihypertensive drug. 12 The Study on Cognition and Prognosis in the Elderly (SCOPE) randomised elderly hypertensive patients to candesartan or placebo. 13 Additional medications were allowed for blood pressure control, so that only 16% of those randomised to placebo remained on placebo only. Consequently, the difference in blood pressure in the two randomised groups was smaller than anticipated and only the numbers of nonfatal strokes were statistically significantly different between the two groups. The Valsartan Antihypertensive Long-term Use Evaluation trial (VALUE) compared valsartan with amlodipine, a calcium channel blocker. 14 In terms of the primary composite end point, there was no significant difference between the treatments. There were more myocardial infarctions and strokes in the valsartan-treated group (P ¼ 0.02 and 0.08, respectively). On the other hand, there were significantly fewer cases of new-onset diabetes among the ARB-treated patients in LIFE and VALUE. The three trials showed conflicting outcomes and raised questions about the benefits and drawbacks of ARB treatment in hypertension. Accordingly, a meta-analysis is needed to provide a better estimate of the impact of ARBs on treatment outcomes in hypertensive patients.
Methods
Searching A computerised literature search was carried out using the Pub-Med database covering the period January 1990-June 2004. The following search terms were used: hypertension, clinical trial, sartan, ARB, angiotensin receptor antagonist, losartan, candesartan, valsartan, irbesartan, eprosartan, telmisartan, olmesartan, coronary disease, coronary heart disease, myocardial infarction, cardiovascular disease, cerebrovascular disease, stroke, diabetes mellitus and heart failure. In addition, the references cited in articles on ARBs and congress abstracts in 2003-2004 were examined.
Selection
Clinical trials of ARBs conducted in humans were identified. There were 252 clinical studies identified in the search, of which 145 were randomised controlled trials. These were reviewed by two researchers independently. Differences were resolved by consensus. The criteria for inclusion in the meta-analysis are: (1) randomised treatment allocation; (2) involving subjects with a primary diagnosis of hypertension at least as a subgroup; (3) no other specified difference in management; (4) double-blinding at least in the assessment of end points; (5) follow up for at least 2 years; (6) a hard end point that is a cardiovascular event or events as the primary or secondary end point; and (7) at least 100 major cardiovascular events. Three trials fitted the criteria and were included in the metaanalysis. 11, 13, 14 
Data abstraction
The following were the main variables abstracted from the trials: number of subjects, prior history of cardiovascular disease, drug name, dosage and duration, the range, mean and s.d. of age, sex, baseline and final blood pressures, all-cause mortality, rates of myocardial infarction, stroke, heart failure and new-onset diabetes mellitus.
The primary end points in the three studies differed. The primary end point in LIFE and SCOPE was cardiovascular mortality, myocardial infarction and stroke. In VALUE, it was cardiac mortality and morbidity, defined as sudden cardiac death, fatal myocardial infarction, death during or after percutaneous coronary intervention or coronary artery bypass graft, death due to heart failure and death associated with recent myocardial infarction on autopsy, heart failure requiring hospital management, nonfatal myocardial infarction, or emergency procedures to prevent myocardial infarction. Notably, stroke was a secondary end point and not part of the primary composite end point.
Study characteristics
The inclusion criteria differed in LIFE, SCOPE and VALUE. In LIFE, hypertensive patients aged 55-80 years with ECG-LVH were recruited. In SCOPE, the subjects were elderly, aged 70-89 years with a treated or untreated systolic blood pressure of 160-179 mmHg or a diastolic blood pressure of 90-99 mmHg, or both, and had a Mini Mental State Examination (MMSE) score of 24 or above. The patients in VALUE were 50 years or older, had treated or untreated hypertension and had cardiovascular risk factors or disease according to an algorithm based on age and sex. 15 The three trials differed in the drug regimens used. The ARBs studied were losartan, candesartan and valsartan in LIFE, SCOPE and VALUE, respectively. The control treatment was atenolol in LIFE and amlodipine in VALUE. In SCOPE, the initial control treatment was placebo, but most patients randomised to placebo received antihypertensive medications to control blood pressure, which included hydrochlorothiazide (62%), calcium channel blocker (28%) and beta-blocker (26%).
Quantitative data synthesis
Relative risk ratios (RRR) were calculated from the number of events in different treatment groups in the clinical trials using a meta-analysis software programme (Comprehensive Meta Analysis,t Biostat Inc., Englewood, NJ, USA). They might differ slightly from the hazard ratios in the trial reports. RRRs were combined using a random effects model (DerSimonian and Laird). 16 For sensitivity analysis, two excluded studies 5, 6 were also analysed to evaluate their impact on the results. Estimates of number-needed-to-treat (NNT) per year were derived from the reciprocal of the annual rate of reduction in absolute risk.
Results

Trial flow
The stages of the meta-analysis are shown in Figure 1 . Table 1 lists the trials used in the meta-analysis together with the respective trial drugs, number and summary characteristics of patients, duration of follow-up, baseline and final blood pressures and blood pressure changes. The SCOPE investigators excluded 27 subjects from all analyses, so the number of subjects with data (4937) was smaller than the total randomized (4964). 13 Primary end point The primary end point was the same in LIFE and SCOPE and not heterogeneous (P ¼ 0.69). The RRR for the primary end point was 0.86 (95% CI: 0.77-0.96, P ¼ 0.008) in LIFE and 0.90 (95% CI: 0.76-1.06, P ¼ 0.19) in SCOPE. The combined RRR was 0.87 (95% CI: 0.80-0.96, P ¼ 0.004) (Figure 2 ). The primary end point was different in VALUE. It included hospitalization for heart failure and emergency procedures to prevent myocardial infarction, and excluded stroke. The RRR for the primary end point in VALUE was 1.02 (95% CI: 0.93-1.12, P ¼ 0.68). Bearing in mind the difference in the definition of the primary end point, combining the results of the three trials yields a RRR of 0.93 (95% CI: 0.82-1.06, P ¼ 0.26, 0.059 for heterogeneity).
Study characteristics
All-cause mortality Figure 3 shows the RRRs for all-cause mortality. None of the trials showed a significant change in allcause mortality. Overall, the RRR was 0.96 (95% CI: 0.88-1.06, P ¼ 0.45, 0.22 for heterogeneity). Figure 4 shows the RRRs for myocardial infarction. There was no significant heterogeneity among the trials (P ¼ 0.68). Overall, the RRR was 1.12 (95% CI: 1.01-1.26, P ¼ 0.041).
Myocardial infarction
Stroke
For stroke, there was significant heterogeneity among the trials (P ¼ 0.00065), but no significant heterogeneity between LIFE and SCOPE (P ¼ 0.87). There were reductions in strokes associated with ARB treatment in LIFE and SCOPE, the RRR being 0.75 (95% CI: 0.63-0.88, P ¼ 0.001) in LIFE and 0.77 (95% CI: 0.59-1.01, P ¼ 0.056) in SCOPE. The combined RRR was 0.75 (95% CI: 0.65-0.87, P ¼ 0.0001). In VALUE, there was an insignificant increase in stroke, the RRR being 1.14 (95% CI: 0.97-1.33, P ¼ 0.11). Heart failure Information on heart failure was available for LIFE and VALUE. In LIFE, the number of heart failure admissions was reported. In VALUE, fatal and nonfatal heart failure were counted. Both studies showed a nonsignificant reduction in heart failure in the ARB-treated group. The RRRs were 0.95 (95% CI: 0.76-1.18, P ¼ 0.62) and 0.88 (95% CI: 0.76-1.01, P ¼ 0.069), respectively. The combined RRR was 0.90 (95% CI: 0.80-1.01, P ¼ 0.073). Figure 5 shows the RRRs for new-onset diabetes. There was no significant heterogeneity among the studies (P ¼ 0.74). The combined estimate of the RRR was 0.80 (95% CI: 0.74-0.86, Po0.0000001).
Diabetes mellitus
The corresponding NNT/year was 255 (95% CI: 189-392).
Sensitivity analysis
There were 144 randomised, controlled trials that were excluded because of not targeting hypertensive subjects, short duration or low number of cardiovascular events. In studies of heart failure 1-4 and myocardial infarction, 17, 18 only a proportion of patients were hypertensive. Two large outcome studies in renal patients were included in the sensitivity analysis because most of the subjects were hypertensive. 5, 6 After including these two studies, the RRR for all-cause mortality becomes Figure 2 RRRs with 95% confidence intervals for the primary end point. The primary end point in LIFE and SCOPE was cardiovascular mortality, myocardial infarction and stroke (end point 1 in Figure) . P ¼ 0.69 for heterogeneity. The primary end point in VALUE was cardiac mortality and morbidity (end point 2). The combined RRR is also shown (P ¼ 0.059 for heterogeneity) for the sake of completeness, although the definition of primary end point varies. Figure 4 RRRs with 95% CI for myocardial infarction. P ¼ 0.68 for heterogeneity.
Primary endpoint
Citation
Myocardial infarction
0.98 (95% CI: 0.92-1.05, P ¼ 0.57). There is no significant heterogeneity among the five studies in this end point (P ¼ 0.48). However, the two studies in renal patients differed widely in the RRR for myocardial infarction (P ¼ 0.010). In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study (RENAAL), the RRR was 0.75 (95% CI: 0.53-1.06, P ¼ 0.10) whereas in the Irbesartan Diabetic Nephropathy Trial (IDNT), it was 1.60 (95% CI: 1.01-2.55, P ¼ 0.045). 19 The incidence of stroke has been reported for IDNT. 19 The RRR for stroke was 1.83 (95% CI: 0.99-3.39, P ¼ 0.051) comparing irbesartan with amlodipine. This differed markedly from the RRRs in the LIFE, SCOPE and VALUE trials (P ¼ 0.028).
Discussion
In this meta-analysis, we found that treatment with ARB, compared to other antihypertensive drug classes, has no statistically significant impact on all-cause mortality. A recent meta-analysis of the effects of ACEIs and ARBs on mortality and renal outcomes in diabetic nephropathy also found a neutral effect of ARB on mortality. 20 Previous meta-analysis of LIFE and SCOPE showed that the composite primary end point was reduced in the ARB group compared to control. 21, 22 In VALUE, there was no such reduction. The definition of primary end point was different in VALUE and included soft end points, but the difference might have been due to poorer blood pressure control in the ARB arm in VALUE. 23 The blood pressure was higher by about 2.0/1.6 mmHg in the valsartantreated group, more so in the first 6 months. Similarly, there were reductions in strokes in the ARB group in LIFE and SCOPE but not in VALUE. Blood pressure differences between groups in LIFE and SCOPE might have systematically overemphasised the benefit from ARB. 24 We now know that even small blood pressure differences may have major effects upon outcome. Overall, there is no evidence to suggest an increase in the rate of the primary end point or stroke in ARB-treated patients. However, the combined RRR for myocardial infarction showed a significant 12% increase. This was heavily influenced by one trial, VALUE, in which valsartan-treated patients achieved inferior blood pressure reductions compared to controls. This might explain the difference in myocardial infarction rates, since in the same trial ARB-treated patients also attained inferior outcomes with respect to strokes. However, the incidence of myocardial infarction was also higher in the ARB arm in LIFE and SCOPE, despite superior blood pressure control. 21, 22, 24 In the two trials of ARB in patients with nephropathy, RENAAL and IDNT, the RRRs for myocardial infarction differed widely. Compared to control, myocardial infarction was reduced in RENAAL but increased in IDNT. In the latter study, irbesartan was substantially better than amlodipine in renal outcomes but inferior in terms of cardiovascular outcomes. In the recently reported Diabetics Exposed to Telmisartan and Enalapril (DETAIL) Study, nonfatal myocardial infarction occurred in nine patients in the telmisartan group and six patients in the enalapril group, while mortality was the same in both groups. 25 The reason for the differences in outcome is controversial. 26 Antihypertensive drug regimens in clinical trials are heterogeneous because different drugs are used for blood pressure control. Thus, the antihypertensive drugs taken by patients in the control arms of LIFE, SCOPE and VALUE were different. While we and others consider it legitimate to combine the results of these studies, 27, 28 interpretation of treatment effects should therefore take into account this heterogeneity. Atenolol and amlodipine, used in the control arm of LIFE and VALUE, respectively, have anti-ischaemic properties and might have biased the results in their favour. Be that as it may, a reduction in the number of myocardial infarctions has a definite clinical value.
To appreciate the overall merits of an intervention, it is imperative to gauge potential benefits against potential harm using an appropriate measure. In this regard, relative risk is less informative than absolute risk, and its reciprocal, NNT. In our analysis, a clinically and statistically significant worthwhile benefit was evident with respect to prevention of new-onset diabetes mellitus. The reduction in new-onset diabetes partly offsets any increase in the risk of myocardial infarction. In contrast, treatment of hypertension with diuretics reduces strokes and myocardial infarction in the short and medium term, but increases the likelihood of developing diabetes. 10 The duration of clinical trials is not long enough for complications of new-onset diabetes to emerge and be translated 
New-onset diabetes
Favours control Figure 5 RRRs with 95% CI for new-onset diabetes mellitus. P ¼ 0.74 for heterogeneity.
Meta-analysis of trials of ARB in hypertension BMY Cheung et al to cardiovascular events. Long-term treatment with ARB may therefore give rise to an array of health benefits. Our results support the use of ARB in the novel indication of prevention of new-onset diabetes in hypertensive patients. ACEIs and ARBs both appear to reduce the incidence of diabetes, [27] [28] [29] although the mechanisms remain unclear at present. We found a trend towards reduction in heart failure with ARB therapy. Although this is expected because of the heart failure trials, 1-4 our finding suggests that heart failure is a comorbidity indicating the use of ARB for the treatment of hypertension in such patients.
Our overview of the results does not support claims that ARBs are superior in preventing myocardial infarction and stroke. On the other hand, the marginal increase in the risk of myocardial infarction shown in our meta-analysis is not serious enough to warrant any warning against the use of ARB in hypertension, 30 although starting treatment with valsartan alone at low dose, as in VALUE, appears to be hazardous. However, the majority of hypertensive patients require more than one class of drugs. Hypertension affects one-fifth of the general population and more than half of the elderly. Unfortunately, just over half are on treatment and good control is achieved in fewer than half of those. 31 The priority must therefore be the detection of hypertension and other risk factors in the community, and achieving good blood pressure control. ARBs are well tolerated and may reduce new-onset diabetes. Large clinical trials and metaanalyses uncover small differences in treatment outcome between drugs; these pale into insignificance when compared to the overriding importance of good blood pressure control. type What is known on this topic K Angiotensin receptor blockers are widely used for the treatment of hypertension K Their benefit in the treatment of hypertension was evaluated in a number of large outcome trials
What this paper adds K Small differences in treatment outcome between drugs are uncovered in large clinical trials and meta-analyses K Angiotensin receptor blockers reduce new-onset diabetes, but may increase the risk of heart attacks slightly
